Trevi Therapeutics, Inc. (TRVI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Jennifer L. Good | Co-Founder, CEO, President & Director | 835.9k | -- | 1965 |
| Dr. Thomas R. Sciascia M.D. | Co-Founder & Chief Scientific Officer | 551.43k | -- | 1953 |
| Dr. James V. Cassella Ph.D. | Chief Development Officer | 50k | -- | 1955 |
| Ms. Lisa Delfini | Chief Financial Officer | -- | -- | 1970 |
| Mr. Christopher Galletta | Controller & Chief Accounting Officer | -- | -- | 1978 |
| Katie McManus | Communications Manager | -- | -- | -- |
| Mr. Farrell Simon Pharm.D. | Chief Commercial Officer | -- | -- | -- |
| Ms. Danine Summers | Vice President of Medical Affairs | -- | -- | 1958 |
Trevi Therapeutics, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 26
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Corporate Governance
Upcoming Events
November 7, 2024 at 10:59 AM UTC - November 11, 2024 at 12:00 PM UTC
Trevi Therapeutics, Inc. Earnings Date